News

Medidata’s suite of technologies is supporting the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which is expected to enroll 30,000 participants. The Medidata and

NIAID is part of the National Institutes of Health, which is an agency of the US Department of Health and Human Services. The trial will target patients who

The study also met key secondary endpoints, significantly improving failure-free survival and patient-reported symptoms assessed by a validated chronic GvHD-specific score. These topline results build on positive data

Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate

BNT162, which is being developed for giving protection against SARS-CoV-2, the virus that causes Covid-19, was recently given the fast track designation by the US Food and Drug

The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel

According to Jnana Therapeutics, the small molecule drugs will be developed for targeting the solute carrier (SLC) family of metabolite transporters for regulating cellular metabolism. The Massachusetts-based biotech

The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action

Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an